SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Genaera Corp
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dave Mordis who wrote (60)9/14/2005 12:17:54 AM
From: DewDiligence_on_SI   of 96
 
Thanks, Dave, for your perspective.

Just to be clear on the systemic-safety matter: it is not my contention that Evizon necessarily does have safety problems. Rather, my view is that it would be surprising if it turned out that a systemically-administered anti-angiogenic drug were efficacious in the eye without having at least some mechanistic side effects common to anti-angio drugs as a class.

Moreover, in preclinical studies, Evizon was not efficacious when given by intravitreal injection.

If you are long GENR, I think your biggest worry—until there are compelling data from a controlled study—should be the worry that Evizon might be a glorified placebo that doesn’t do much of anything, good or bad. Regards, Dew
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News